Corporate Events

Sumitomo Pharma Co., Ltd. reported earnings results for the first quarter ended June 30, 2026. For the first quarter, the company reported sales was JPY 129,495 million compared to JPY 108,002 million a year ago. Net income was JPY 16,997 million compared to JPY 11,206 million a year ago. Basic earnings per share from continuing operations was JPY 39.02 compared to JPY 28.21 a year ago.

Sumitomo Pharma Co., Ltd., Q1 2027 Earnings Call, Jul 31, 2026

Sumitomo Pharma Co., Ltd.(TSE:4506) added to S&P Japan 500

Sumitomo Pharma Co., Ltd. has completed a Follow-on Equity Offering in the amount of ¥102.095756 billion. Security Name: Common Stock Security Type: Common Stock Securities Offered: 21,804,400 Price\Range: ¥1990 Security Name: Common Stock Security Type: Common Stock Securities Offered: 29,500,000 Price\Range: ¥1990 Transaction Features: Rule 144A

Sumitomo Pharma Co., Ltd. reported earnings results for the full year ended March 31, 2026. For the full year, the company reported sales was JPY 453,294 million compared to JPY 398,832 million a year ago. Net income was JPY 106,865 million compared to JPY 23,634 million a year ago. Basic earnings per share from continuing operations was JPY 268.99 compared to JPY 59.49 a year ago.

Sumitomo Pharma Co., Ltd., Annual General Meeting, Jun 25, 2026, at 10:00 Tokyo Standard Time. Location: Hall on the 7th floor of the Company's Corporate Headquarters Building 6-8, Doshomachi 2-chome, Chuo-ku, Osaka Japan Agenda: To consider business report, consolidated financial statements, and non-consolidated financial statements for the 206th fiscal year (from april 1, 2025 to march 31, 2026); to consider audit report of the accounting auditor and audit report of the audit and supervisory committee on the consolidated financial statements; to consider election of six directors excluding directors who are audit and supervisory committee members; and to transact such other business matters.

SMBC Nikko Securities Inc. has been added as the Co-Lead Underwriter for Sumitomo Pharma Co., Ltd.'s ¥102.095756 billion Follow-on Equity Offering.

Daiwa Capital Markets Europe Limited has been added as the Co-Lead Underwriter for Sumitomo Pharma Co., Ltd.'s ¥102.095756 billion Follow-on Equity Offering.

Nomura international Plc has been added as the Co-Lead Underwriter for Sumitomo Pharma Co., Ltd.'s ¥102.095756 billion Follow-on Equity Offering.

Mizuho International plc has been added as the Co-Lead Underwriter for Sumitomo Pharma Co., Ltd.'s ¥102.095756 billion Follow-on Equity Offering.

Sumitomo Pharma Co., Ltd. announced that they will report Q1, 2027 results on Jul 31, 2026

Sumitomo Pharma Co., Ltd. announced that they will report fiscal year 2026 results at 1:00 PM, Tokyo Standard Time on May 13, 2026

Sumitomo Pharma Co., Ltd., 2026 Earnings Call, May 13, 2026

Sumitomo Pharma Co., Ltd. has filed a Follow-on Equity Offering. Security Name: Common Stock Security Type: Common Stock

Sumitomo Pharma Co., Ltd., Board Meeting, Apr 08, 2026. Agenda: To consider and approve the Issuance of New Shares and Secondary Offering of Shares.

Sumitomo Pharma Co., Ltd. revised consolidated earnings guidance for the fiscal year ending March 31, 2026. For the year, the company revised revenue of JPY 449,000 million compared to previous guidance of JPY 429,000 million. Core operating profit of JPY 107,000 million compared to previous guidance of JPY 97,000 million. Operating profit of JPY 108,000 million compared to JPY 98,000 million. Net profit attributable to owners of the parent of JPY 102,000 million compared to previous guidance of JPY 92 million. Basic earnings per share of JPY 256.74 per share compared to previous guidance of JPY 231.57 per share. Reasons for the revisions: In the revised forecasts announced today, the Company has changed the full-year foreign exchange assumption (average exchange rate for the period) from JPY 145.0 to JPY 150.0 against 1 USD, as compared with the previous forecast. Revenue has been revised upward by JPY 20.0 billion to JPY 449.0 billion, reflecting higher than expected sales of products such as GEMTESA (therapeutic agent for overactive bladder) in the North America segment, as well as the positive impact of the weaker yen. Core operating profit has been revised upward by JPY 10.0 billion to JPY 107.0 billion. In addition to the increase in gross profit resulting from higher revenue, selling, general and administrative expenses and R&D expenses are now expected to be slightly lower than the previous forecast, excluding the impact of yen depreciation. Driven by the increase in core operating profit, operating profit has been revised upward by JPY 10.0 billion to JPY 108.0 billion and profit attributable to owners of the parent has been revised upward by JPY 10.0 billion to JPY 102.0 billion, compared with the previous forecast.

Sumitomo Pharma Co., Ltd., Board Meeting, Mar 02, 2026. Agenda: To consider and approve Filing of Shelf Registration Statement for Issuance of New Shares.

Presentation of Boost 2028 - Accelerating Strong Sumitomo Pharma -

Sumitomo Pharma Co., Ltd. and RACTHERA Inc. submitted, on August 5, 2025, an application of manufacturing and marketing authorization for allogeneic iPS cell-derived dopaminergic neural progenitor cells for indication of the improvement of motor functions during the off-time period of patients with advanced Parkinson's disease. Sumitomo Pharma and RACTHERA announced that the regenerative medical product AMCHEPRY has been listed as an item for deliberation on the agenda of the upcoming meeting of the Ministry of Health, Labour and Welfare's Pharmaceutical Affairs and Food Sanitation Council, Committee on Regenerative Medicine Products and Biotechnologies, scheduled to be held on February 19, 2026.

Sumitomo Pharma Co., Ltd. reported earnings results for the nine months ended December 31, 2025. For the nine months, the company reported sales was JPY 347,746 million compared to JPY 293,183 million a year ago. Net income was JPY 107,677 million compared to JPY 21,219 million a year ago. Basic earnings per share from continuing operations was JPY 271.03 compared to JPY 53.41 a year ago.

R&D meeting

Sumitomo Pharma Co., Ltd. expected to report Fiscal Year 2026 results on May 13, 2026. This event was calculated by S&P Global (Created on January 30, 2026).

Sumitomo Pharma Co., Ltd., Q3 2026 Earnings Call, Jan 30, 2026

Sumitomo Pharma Co., Ltd. Presents at The 67th American Society of Hematology (ASH) Annual Meeting, Dec-06-2025 . Venue: Orange County Convention Center (OCCC), Orlando, Florida, United States.

Sumitomo Pharma Co., Ltd. revised earnings guidance for the half-year ended September 30, 2025 and full year ending March 31, 2026. For the half year, the company now expects revenue of JPY 227,122 million, Operating profit of JPY 96,157 million, Net profit attributable to owners of parent of JPY 98,860 million, and Earnings per share of JPY 248.84 as compared to revenue of JPY 207,000 million, Operating profit of JPY 69,000 million, Net profit attributable to owners of parent of JPY 56,000 million, and Earnings per share of JPY 140.96 in the previous forecasts. For the full year, the company now expects revenue of JPY 429,000 million, Operating profit of JPY 98,000 million, Net profit attributable to owners of parent of JPY 92,000 million, and Earnings per share of JPY 231.57 as compared to revenue of JPY 355,000 million, Operating profit of JPY 54,000 million, Net profit attributable to owners of parent of JPY 40,000 million, and Earnings per share of JPY 100.68 in the previous forecasts. Revenue exceeded the previously announced forecast primarily due to strong sales of ORGOVYX® (therapeutic agent for advanced prostate cancer) in the North America segment. On the other hand, selling, general and administrative expenses and R&D expenses were lower than expected, resulting in some expenses likely being recorded in the second half of the fiscal year. Consequently, for the six-month period ended September 30, 2025, revenue increased by 20.1 billion JPY to 227.1 billion JPY, core operating profit increased by 26.1 billion JPY to 96.1 billion JPY, and operating profit increased by 27.2 billion JPY to 96.2 billion JPY from the previous forecasts. Net profit attributable to owners of the parent increased by 42.9 billion JPY from the previous forecast to 98.9 billion JPY, due to increased operating profit, improved financial income/costs resulting from the weaker-than-expected Japanese yen, and the recording of a gain on the reversal of deferred tax liabilities. Revenue has been revised upward by 74.0 billion JPY from the previous forecast to 429.0 billion JPY, reflecting the expectation of continued strong sales in North America. Core operating profit has been revised upward by 41.0 billion JPY from the previous forecast to 97.0 billion JPY, as the gains from the divestiture of the Asian business are expected to exceed initial forecast, while gross profit is expected to increase due to revenue growth. Operating profit has been revised upward by 44.0 billion JPY to 98.0 billion JPY from the previous forecast due to increased core operating profit, and net profit attributable to owners of the parent has been revised upward by 52.0 billion JPY to 92.0 billion JPY, taking into account a decrease in tax expenses and other costs in the first half of the fiscal year. The full-year foreign exchange assumption (average exchange rate for the period) remains unchanged from the previous forecast at 145.0 JPY against 1 USD.

Sumitomo Pharma Co., Ltd. announced that they will report Q3, 2026 results at 3:30 PM, Tokyo Standard Time on Jan 30, 2026

Sumitomo Pharma Co., Ltd. expected to report Q3 2026 results on January 30, 2026. This event was calculated by S&P Global (Created on October 31, 2025).